STUDY OF HER2 NEU POSITIVITY IN GASTROINTESTINAL CANCERS AT A TERTIARY CARE HOSPITAL IN INDIA

Introduction- HER2 is now well recognized as a key factor in the development of certain solid human tumors .The expression of Her2/ Neu in gastrointestinal malignancies is new concept with paucity of literature. Aim- The present study was conducted in a tertiary care cancer hospital in India to evaluate Clinicopathological features in resected cases of gastrointestinal cancer cases and their correlation with Her2/Neu expression by Immunohistochemistry. Material & Methods- The present study was carried out in department of pathology at regional cancer tertiary centre from October 2017 to October 2019. The cases were selected on basis of inclusion & exclusion criteria.Her2/Neu expression was assessed in all 100 cases. Results- In present study HER2/neu status was determined on 100 cases by immune histochemistry and all IHC 3+ are accepted as HER2/neu positive cases, 2+ were equivocal and 1+/0 were negative. Out of 100 cases, 8 cases (8%) show HER2/neu 3+, 5 cases were HER2/neu 2+, 20 cases showed HER2/neu 1+ score and 67 cases showed Her2 Neu score 0. The mean age of all tumors was 53.7year (Standard Deviation 14.08 ) (P =0.59). Mean age of gastric and GEJ cancer 57.1 year (SD-12.01), small intestine cancer 57.7 year (SD-7.41), pancreatobiliary cancer 55.50 year (SD-14.86),colon cancer 54.5 year (SD-13.94),rectal cancer 52.1 year (SD- 15.45).Out of 100 cases , 59 cases were male and 41 were female (M:F= 1.4:1In the GIT tumors no statistically signicant association was found between her2/ neu status with histological type , T stage , size of tumor , grade and TNM stage . The only signicant association of Her/ 2 Neu was found with Modied Astler coller staging. Conclusion- Modied Astler Coller stage can be used as screening test for centers where facility of Her2neu test not available.

Results of diagnosis and surgery of small bowel cancer at Bach Mai Hospital

Tóm tắt Đặt vấn đề: Ung thư ruột non là khối u hiếm gặp, thường được chẩn đoán và phẫu thuật ở giai đoạn muộn khi biến chứng đã xảy ra. Nghiên cứu nhằm mô tả đặc điểm lâm sàng, cận lâm sàng, đánh giá kết quả phẫu thuật ung thư ruột non. Phương pháp nghiên cứu: Nghiên cứu mô tả, hồi cứu 45 người bệnh (NB) ung thư ruột non nguyên phát được phẫu thuật tại Bệnh viện Bạch Mai từ 2012 đến 2016. Thu thập các đặc điểm lâm sàng, cận lâm sàng, chẩn đoán trước mổ, mô bệnh học, kết quả điều trị và thời gian sống thêm. Kết quả: 45 NB gồm 23 nam, 22 nữ, hay gặp ở nhóm 41 đến 60 tuổi. Triệu chứng đa dạng, không đặc hiệu và thay đổi theo thể giải phẫu bệnh, có 64,4% chẩn đoán được trước mổ là u ruột non. Chụp cắt lớp vi tính chẩn đoán chính xác 56,7%. Thể saccom cơ trơn gặp nhiều nhất (51,1%), carcinoid gặp ít nhất (4,4%). Kết quả điều trị không có tử vong, 8,9% nhiễm trùng vết mổ. Thời gian sống thêm sau mổ trung bình là 71,1 ± 1,98 tháng, thể ung thư biểu mô tuyến ngắn nhất 22,1 ± 9,5 tháng, thể u carcinoid dài nhất 54,7 ± 12,2 tháng, tuổi >30 tiên lượng tốt hơn nhóm < 30. Kết luận: Ung thư ruột non vẫn còn khó chẩn đoán đúng trước mổ. Điều trị phẫu thuật có hiệu quả tốt và tiên lượng phụ thuộc lứa tuổi và thể mô bệnh học. Abstract Introduction: Small intestine cancer is a rare tumor that is usually diagnosed and operated at a later stage when complications have occurred. Objectives: Describe clinical, subclinical characteristics and surgical results of small intestine cancer. Tạp chí Phẫu thuật nội soi và Nội soi Việt Nam (2020) Số 5 - Tập 10; 27 - 32 27 Kết quả chẩn đoán và điều trị phẫu thuật ung thư ruột non tại Bệnh viện Bạch Mai Trần Hiếu Học và cộng sự Materials and Methods: Descriptive and longitudinal study on 45 patients of primary small bowel cancer operated at Bach Mai Hospital from 2012 to 2016. Data included clinical, subclinical characteristics, diagnosis, histopathology, results of treatment and survival time. Results: The study has 45 patients (23 males and 22 females), most of them aged 41 - 60. Symptoms are diverse, nonspecific and vary according to disease anatomy, correct preoperative diagnosis of small bowel tumor was 64.4% and sensitivity of CT was 56.7%. Frequency of Sarcoma was highest (51.1%) and of carcinoid was least (4.4%). There was no postoperative mortality, 8.9% incision infection. The survival time is 71.1 ± 1.98 months, shortest belongs to carcinoma (22,1 ± 9,5 months) and longest belongs to carcinoid (54,7 ± 12,2 months), prognosis is better in the age group over 30. Conclusions: Proper preoperative diagnosis of small bowel cancer is still difficult. Surgical treatment is effective and prognosis depends on age and histopathology. Keywords: Small bowel cancer, surgery, survival time.

Positive Fecal Immunochemical Test Results Are Associated with Increased Risks of Esophageal, Stomach, and Small Intestine Cancers

Background: The current guideline does not recommend upper gastrointestinal evaluation for patients with a positive fecal immunochemical test (FIT) and negative colonoscopy results. However, this indication was based on low-quality evidence as data on this issue are very limited. We assessed the risk of proximal cancers (oral or throat, esophageal, stomach, and small intestine cancers) after negative or positive FIT results in the Korean National Cancer Screening Program (NCSP). Methods: Using the NCSP databases, we collected data on participants who underwent FIT between 2009 and 2011. Participants were classified based on FIT results and colorectal cancer (CRC) diagnosed within 1 year after FIT as FIT− (n = 5,551,755), FIT+/CRC− (n = 368,553), and FIT+/CRC+ (n = 12,236). Results: The incidence rates of overall proximal cancers in FIT−, FIT+/CRC−, and FIT+/CRC+ patients within 1, 2, and 3 years after FIT were 0.38%, 0.68%, and 2.26%; 0.57%, 0.93%, and 2.74%; and 0.79%, 1.21%, and 3.15%, respectively. After adjusting confounding variables, the risks of esophageal, stomach, and small intestine cancers as well as overall proximal cancers within 1, 2, and 3 years after FIT were higher in FIT+/CRC− patients than those in FIT− patients. However, the risk of oral or throat cancer did not differ between FIT− and FIT+/CRC− patients. The risks for oral or throat cancer and small intestine cancer were higher in FIT+/CRC+ patients than those in FIT+/CRC− patients. Conclusions: In this population-based study, FIT+/CRC− patients were at higher risk for esophageal, stomach, and small intestine cancers than were FIT− patients, suggesting that positive FIT results were associated with these cancers.